These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26177509)

  • 1. Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia.
    Sivagnanalingam U; Balys M; Eberhardt A; Wang N; Myers JR; Ashton JM; Becker MW; Calvi LM; Mendler JH
    PLoS One; 2015; 10(7):e0132375. PubMed ID: 26177509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
    Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
    DeAngelo DJ; Stein EM; Ravandi F
    Am Soc Clin Oncol Educ Book; 2016; 35():e302-12. PubMed ID: 27249736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
    Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
    Hickey CJ; Schwind S; Radomska HS; Dorrance AM; Santhanam R; Mishra A; Wu YZ; Alachkar H; Maharry K; Nicolet D; Mrózek K; Walker A; Eiring AM; Whitman SP; Becker H; Perrotti D; Wu LC; Zhao X; Fehniger TA; Vij R; Byrd JC; Blum W; Lee LJ; Caligiuri MA; Bloomfield CD; Garzon R; Marcucci G
    Blood; 2013 Jan; 121(1):159-69. PubMed ID: 23100311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
    J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
    Khan M; Cortes J; Kadia T; Naqvi K; Brandt M; Pierce S; Patel KP; Borthakur G; Ravandi F; Konopleva M; Kornblau S; Kantarjian H; Bhalla K; DiNardo CD
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia.
    Nachmias B; Krichevsky S; Filon D; Even-Or E; Gatt ME; Saban R; Avni B; Grisariu S; Aumann S; Vainstein V
    Acta Haematol; 2022; 145(6):642-649. PubMed ID: 35933982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemogenomic Landscape of
    Simon L; Lavallée VP; Bordeleau ME; Krosl J; Baccelli I; Boucher G; Lehnertz B; Chagraoui J; MacRae T; Ruel R; Chantigny Y; Lemieux S; Marinier A; Hébert J; Sauvageau G
    Clin Cancer Res; 2017 Nov; 23(22):6969-6981. PubMed ID: 28855357
    [No Abstract]   [Full Text] [Related]  

  • 10. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
    Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
    Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?
    Foley N; Van Ziffle J; Yu J; Qi Z; Grenert JP; Yeh I; Bastian B; Kogan S; Mannis GN
    Cancer Genet; 2017 Oct; 216-217():74-78. PubMed ID: 29025598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated Bone Marrow Non-Langerhans Cell Histiocytosis Preceding RUNX1-Mutated Acute Myeloid Leukemia: Case Report and Literature Review.
    Al Mugairi A; Al Turki S; Salama H; Al Ahmadi K; Abuelgasim KA; Damlaj M
    Am J Clin Pathol; 2019 May; 151(6):638-646. PubMed ID: 30989185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.
    Höllein A; Jeromin S; Meggendorfer M; Fasan A; Nadarajah N; Kern W; Haferlach C; Haferlach T
    Leukemia; 2018 Oct; 32(10):2270-2274. PubMed ID: 29568097
    [No Abstract]   [Full Text] [Related]  

  • 14. RUNX1 Mutations Can Lead to Aberrant Expression of CD79a and PAX5 in Acute Myelogenous Leukemias: A Potential Diagnostic Pitfall.
    Menter T; Lundberg P; Wenzel F; Dirks J; Fernandez P; Friess D; Dirnhofer S; Tzankov A
    Pathobiology; 2019; 86(2-3):162-166. PubMed ID: 30396184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH).
    Munker R; Nordberg ML; Veillon D; Williams BJ; Roggero A; Kern W; Dicker F; Haferlach T
    Leuk Res; 2009 Oct; 33(10):1405-8. PubMed ID: 19414191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models.
    Lal D; Park JA; Demock K; Marinaro J; Perez AM; Lin MH; Tian L; Mashtare TJ; Murphy M; Prey J; Wetzler M; Fetterly GJ; Wang ES
    Mol Cancer Ther; 2010 Oct; 9(10):2737-51. PubMed ID: 20924124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.
    Delsing Malmberg E; Rehammar A; Pereira MB; Abrahamsson J; Samuelsson T; Ståhlman S; Asp J; Tierens A; Palmqvist L; Kristiansson E; Fogelstrand L
    J Mol Diagn; 2019 Jan; 21(1):149-162. PubMed ID: 30273780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
    Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
    Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
    Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
    Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RUNX1/CEBPA Mutation in Acute Myeloid Leukemia Promotes Hypermethylation and Indicates for Demethylation Therapy.
    Romanova EI; Zubritskiy AV; Lioznova AV; Ogunleye AJ; Golotin VA; Guts AA; Lennartsson A; Demidov ON; Medvedeva YA
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.